Growth & profitability
- Revenue has declined 45.8% per year over the past 5 years.
- Operating margin has expanded, at -145.3% in the latest year.
Financial health
- Total debt has grown faster than revenue (36.9% vs -45.8% per year).
TXMD Financials TherapeuticsMD, Inc.
15 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
RevenueNet income
GrossOperatingNet
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key annual figures
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $3M | -$569000 | 0.0% | -145.3% | — | — | $7M |
| 2024 | $2M | -$2M | 0.0% | -347.1% | — | — | $5M |
| 2023 | $1M | -$10M | 100.0% | -654.6% | — | — | $4M |
| 2022 | $70M | $112M | 98.0% | 1.7% | — | — | $49M |
| 2021 | $3M | -$172M | 45.5% | -3092.8% | -$55M | $188M | $65M |
| 2020 | $65M | -$184M | 75.4% | -239.8% | — | $238M | $80M |
| 2019 | $50M | -$176M | 87.2% | -304.6% | — | $195M | $161M |
| 2018 | — | -$133M | — | — | — | $73M | $162M |
| 2017 | — | -$77M | — | — | — | — | $127M |
| 2016 | — | -$90M | — | — | — | — | $132M |
| 2015 | — | -$85M | — | — | — | — | — |
| 2014 | — | -$54M | — | — | — | — | — |
| 2013 | — | -$28M | — | — | — | — | — |
| 2012 | — | -$35M | — | — | — | — | — |
| 2011 | — | -$13M | — | — | — | — | — |
RevenueNet income
GrossOperatingNet
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key quarterly figures
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $724000 | $95000 | 0.0% | -99.9% | — | — | $8M |
| Dec '25 | — | -$619000 | — | — | — | — | $7M |
| Sep '25 | — | $152000 | — | — | — | — | $7M |
| Jun '25 | — | $551000 | — | — | — | — | $6M |
| Mar '25 | $393000 | -$653000 | 0.0% | -326.0% | — | — | $6M |
| Dec '24 | — | $252000 | — | — | — | — | $5M |
| Sep '24 | — | -$609000 | — | — | — | — | $5M |
| Jun '24 | — | -$1M | — | — | — | — | $5M |
| Mar '24 | — | -$734000 | — | — | — | — | $4M |
| Dec '23 | — | -$883000 | — | — | — | — | $4M |
| Sep '23 | — | -$3M | — | — | — | — | $49M |
| Jun '23 | — | -$2M | — | — | — | — | $14M |
| Mar '23 | — | -$4M | — | — | — | — | $49M |
| Dec '22 | — | $78M | — | — | — | — | $49M |
| Sep '22 | — | -$29M | — | — | $18M | $94M | $65M |
| Jun '22 | — | $112M | — | — | — | $91M | $65M |
| Mar '22 | — | -$49M | — | — | — | $203M | $65M |
| Dec '21 | — | -$43M | — | — | — | $188M | $65M |
| Sep '21 | — | -$47M | — | — | — | $187M | $105M |
| Jun '21 | — | -$43M | — | — | — | $185M | $111M |
Valuation over time
How the market has priced TXMD against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
- The price-to-sales ratio has risen from 0.6× (Mar '23) to 7.8× (Jun '26).
P/S
Frequently asked questions
Is TXMD growing its revenue and profit?
Over the past 5 years, TherapeuticsMD, Inc.'s revenue has declined 45.8% per year. These are computed facts, not advice.
How much debt does TXMD have?
As of FY2025, TherapeuticsMD, Inc. reported — of total debt against $7M of cash.
What is TXMD's profit margin?
In FY2025, gross margin was —, operating margin -145.3%, and net margin -18.8%.
Where does this data come from?
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.